Acalabrutinib + Venetoclax for CLL

(MAVRiC Trial)

This trial tests a combination of two drugs, acalabrutinib and venetoclax, to determine their effectiveness and safety for individuals with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have relapsed after previous treatments. The trial aims to discover if these drugs together can benefit those who responded well to earlier therapy and remained cancer-free for at least two years. Individuals previously treated with specific medications for CLL/SLL and who maintained a positive response might be suitable candidates for the trial. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, providing an opportunity to contribute to significant findings.

The trial requires that you do not take certain medications, such as strong CYP3A4 inhibitors/inducers and anticoagulants like warfarin. If you are on these medications, you may need to stop them before participating.

Research shows that the combination of acalabrutinib and venetoclax is generally well-tolerated by patients. In earlier studies, a rare but serious side effect called tumor lysis syndrome, where cancer cells break down quickly, occurred in only about 0.3% of patients. Additionally, more than 90% of patients initially at high risk for this condition saw their risk decrease to low or medium after two cycles of acalabrutinib.

Researchers are excited about the combination of Acalabrutinib and Venetoclax for treating Chronic Lymphocytic Leukemia (CLL) because it offers a novel approach by targeting different pathways crucial for cancer cell survival. Acalabrutinib works by inhibiting the Bruton's tyrosine kinase (BTK) pathway, which is essential for CLL cell growth, while Venetoclax induces cancer cell death by targeting the B-cell lymphoma 2 (BCL-2) protein. This dual mechanism of action could potentially lead to more effective and quicker results compared to standard treatments like chemotherapy or single-drug therapies. Additionally, the combination aims to improve long-term outcomes and reduce the need for prolonged treatment durations, which is a significant advantage over current options.

Research has shown that combining acalabrutinib and venetoclax holds promise for treating certain blood cancers, such as chronic lymphocytic leukemia (CLL). One study found that this combination resulted in 94.1% of patients being alive after three years. Another study reported that 70% of patients experienced no disease progression over four years. These findings suggest that this treatment, which participants in this trial will receive, effectively controls cancer and improves survival rates.²⁶⁷⁸